相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer
Megan E. Tesch et al.
CANCER (2022)
Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care
Deirdre Weymann et al.
JOURNAL OF COMMUNITY GENETICS (2022)
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
Wei Fang Dai et al.
JAMA ONCOLOGY (2022)
Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada
Andrea M. Guggenbickler et al.
CURRENT ONCOLOGY (2022)
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer
Vanessa Arciero et al.
JNCI CANCER SPECTRUM (2022)
Economic evaluation of robot-assisted radical prostatectomy compared to open radical prostatectomy for prostate cancer treatment in Ontario, Canada
Anna Parackal et al.
CUAJ-Canadian Urological Association Journal (2020)
Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy
Lucy Gilbert et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis
A. J. N. Raymakers et al.
BMC CANCER (2020)
Cost-effectiveness analyses using real-world data: an overview of the literature
Kevin Bowrin et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future
Josephine Mauskopf
VALUE IN HEALTH (2019)
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
Jeffrey S. Hoch et al.
BMC CANCER (2019)
Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials
Narjust Duma et al.
ONCOLOGIST (2019)
Primary versus Tertiary Care Follow-Up of Low-Risk Differentiated Thyroid Cancer: Real-World Comparison of Outcomes and Costs for Patients and Health Care Systems
Syed Ali Imran et al.
EUROPEAN THYROID JOURNAL (2019)
Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay
Nicole Mittmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence
Sara Nazha et al.
CLINICAL DRUG INVESTIGATION (2018)
Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting
S. Nazha et al.
CURRENT ONCOLOGY (2018)
The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency
Sonya Cressman et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting
Hla-Hla Thein et al.
CANCER MEDICINE (2017)
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
Sara Khor et al.
BMC CANCER (2014)
Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial
Eva Grunfeld et al.
BMC FAMILY PRACTICE (2013)
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer
Malek B. Hannouf et al.
BMC CANCER (2012)
Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada
Lindsay Hedden et al.
EUROPEAN JOURNAL OF CANCER (2012)
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis
Ian Cromwell et al.
LUNG CANCER (2012)
Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer
Lindsay Hedden et al.
ONCOLOGIST (2012)
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
Ian Cromwell et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada
Karissa M. Johnston et al.
VALUE IN HEALTH (2010)
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis
Bas Groot Koerkamp et al.
MEDICAL DECISION MAKING (2007)
分享论文
